These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 8092158)

  • 41. Pharmacoeconomic analyses: whose perspective counts and costs the most?
    Rubenstein EB; Elting LS
    Am J Hosp Pharm; 1994 Jun; 51(12):1564-9. PubMed ID: 8092157
    [No Abstract]   [Full Text] [Related]  

  • 42. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.
    Zbrozek AS; Cantor SB; Cardenas MP; Hill DP
    Am J Hosp Pharm; 1994 Jun; 51(12):1555-63. PubMed ID: 8092156
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
    Lachaine J; Laurier C; Langleben A; Vaillant L
    Crit Rev Oncol Hematol; 1999 Nov; 32(2):105-12. PubMed ID: 10612010
    [No Abstract]   [Full Text] [Related]  

  • 44. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy.
    Kwong WJ; Parasuraman TV
    Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness, not cost containment.
    Zbrozek AS
    Am J Hosp Pharm; 1994 Jun; 51(12):1569-71. PubMed ID: 8092158
    [No Abstract]   [Full Text] [Related]  

  • 46. Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
    Kris MG
    Important Adv Oncol; 1994; ():165-77. PubMed ID: 8206488
    [No Abstract]   [Full Text] [Related]  

  • 47. [Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin].
    Harousseau JL
    Bull Cancer; 1996 Jan; 83(1):71-76. PubMed ID: 8672859
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 49.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 50.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.